Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancer

[1]  F. Couch,et al.  Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups , 2016, Breast Cancer Research.

[2]  I. Ellis,et al.  Impact of tissue sampling on accuracy of Ki67 immunohistochemistry evaluation in breast cancer , 2016, Diagnostic Pathology.

[3]  Matthieu Resche-Rigon,et al.  18F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen , 2016, The Journal of Nuclear Medicine.

[4]  Keda Yu,et al.  New insights into the prognostic value of Ki-67 labeling index in patients with triple-negative breast cancer , 2016, Oncotarget.

[5]  D. Groheux,et al.  18F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  Alexandre Cochet,et al.  Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer , 2015, Clinical Cancer Research.

[7]  Gideon Blumenthal,et al.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.

[8]  M. Hatt,et al.  Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer. , 2014, European journal of cancer.

[9]  H Tesch,et al.  Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  H. Sasano,et al.  Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy , 2013, Breast Cancer Research and Treatment.

[11]  C. Perou,et al.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  C. Sotiriou,et al.  Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  D. Groheux,et al.  Prognostic Impact of 18FDG-PET-CT Findings in Clinical Stage III and IIB Breast Cancer , 2012, Journal of the National Cancer Institute.

[14]  Stefan Michiels,et al.  Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Gelber,et al.  Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  Patrick Royston,et al.  Visualizing and assessing discrimination in the logistic regression model , 2010, Statistics in medicine.

[17]  Benjamin Haibe-Kains,et al.  Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues , 2009, BMC Genomics.

[18]  C. Sotiriou,et al.  Genomic grade index is associated with response to chemotherapy in patients with breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. J. van de Vijver,et al.  Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. , 2006, Journal of the National Cancer Institute.

[20]  S. Rodenhuis,et al.  Sequential 18F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  Gang Huang,et al.  Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis , 2011, Breast Cancer Research and Treatment.